Condition
Diffuse Midline Glioma (DMG)
Total Trials
3
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 1 (3)
Trial Status
Recruiting1
Not Yet Recruiting1
Enrolling By Invitation1
Clinical Trials (3)
Showing 3 of 3 trials
NCT04732065Phase 1RecruitingPrimary
ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
NCT07455045Phase 1Not Yet Recruiting
A Phase I Study of FZ-AD005 in Patients With High-Grade Glioma (HGG)
NCT06896110Phase 1Enrolling By Invitation
Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma
Showing all 3 trials